AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1556836
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with BCG (40 mg in 40 ml saline, monthly for 12 months)
Trial: 28940961
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of metformin (MF+)
Trial: 28940961
Drug: Withholding metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding metformin (MF-)
Trial: 28053789
Drug: Capsaicin cream
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin cream applied around participants' ankle during locomotor training (Pain group)
Trial: 24615429
Drug: High-dose omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose omega-3 ethyl esters (n-3 PUFA), 2-4 g daily for 12 weeks
Trial: 20651615
Drug: Docetaxel monotherapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel monotherapy (60 mg/m, day 1, q3 weeks)
Trial: 20651615
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of docetaxel (40 mg/m, day 1, q3 weeks) and S-1 (80 mg/m, days 1-15)
Trial: 20651615
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of docetaxel and S-1
Trial: 17560879
Drug: Ezetimibe/Simvastatin (10/10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Simvastatin (10/10, 10/20, 10/40, or 10/80 mg)
Trial: 17560879
Drug: Simvastatin (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10, 20, 40, or 80 mg)
Trial: 16018379
Drug: Laxomucil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxomucil (2 sachets, 3.26 g plantago ovata, twice daily for 20 days)
Trial: 2914474
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen therapy at 2 L/min
Trial: 2914474
Drug: Nasal air
RxNorm normalized name: nasal airflow strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal air therapy
Trial: 30317291
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg intravenous dexamethasone
Trial: 30317291
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg dexamethasone infiltrated into the peritonsillar regions
Trial: 30317291
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL of 0.5% bupivacaine infiltration
Trial: 18432173
Drug: Rotational atherectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotational atherectomy followed by drug-eluting stent implantation (Rota-DES)
Trial: 18432173
Drug: Drug-eluting stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stent implantation alone (DES)
Trial: 16150034
Drug: Computer-based learning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based learning (CBL) programme covering cardiovascular drug therapy (n = 70)
Trial: 12829911
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CsA) monotherapy
Trial: 12829911
Drug: Azathioprine +
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine + prednisolone dual therapy
Trial: 10827214
Drug: 415 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 415 microg folate/d (as diet plus FA or a combination of FA and OJ)
Trial: 6191495
Drug: Conventional anti-acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anti-acne medications (other than salicylic acid and tretinoin)
Trial: 28575208
Drug: 12 weekly
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weekly doses of directly observed isoniazid and rifapentine (3HP)
Trial: 26638010
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg every-2-weeks (Q2W)
Trial: 26638010
Drug: Double-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose rosuvastatin
Trial: 25129515
Drug: 15% DEET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% DEET topical repellent
Trial: 19234056
Drug: Energy reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy reduction diet (reduce daily intake by 500 kcal and limit energy from fat to <or=25%)
Trial: 12790845
Drug: Single combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single combined preoperative dose of gentamicin (160 mg) and metronidazole (500 mg)
Trial: 12790845
Drug: Postoperative standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative standard scheme of antibiotics over 7 days
Trial: 12790845
Drug: Single combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single combined preoperative dose of gentamicin and metronidazole
Trial: 8836419
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (XRT) as adjuvant after chemotherapy
Trial: 8836419
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (XRT) for partial responders (PRs) after chemotherapy
Trial: 8836419
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (XRT) as salvage treatment for asymptomatic limited nodal relapse
Trial: 8836419
Drug: XRT in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XRT in high-dose therapy programs
Trial: 1734801
Drug: Intramuscular famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular famotidine 20 mg (group F2)
Trial: 1734801
Drug: Intramuscular famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular famotidine 20 mg (group F3)
Trial: 1734801
Drug: Intramuscular saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular saline (placebo, group P2)
Trial: 1734801
Drug: Intramuscular famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular famotidine 20 mg (group F1)
Trial: 1734801
Drug: Intramuscular saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular saline (placebo, group P3)
Trial: 6539662
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg Gemeprost vaginal suppository
Trial: 28341108
Drug: Nab-paclitaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (100 mg/m2 on days 1, 8, and 15 every 3 weeks)
Trial: 25089264
Drug: Mebeverine (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine (135 mg, twice daily)
Trial: 17467553
Drug: Long-term azithromycin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term azithromycin administration
Trial: 10705266
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP) 500 microg 3 times daily for 2 months
Trial: 6476499
Drug: 22% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22% BCAA amino acid solution
Trial: 6476499
Drug: 41% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 41% BCAA amino acid solution
Trial: 6476499
Drug: Control (41%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (41% BCAA amino acid solution)
Trial: 29958022
Drug: Closed loop
RxNorm normalized name: Povidone Iodine 7.5% Topical application Liquid [OPERAND CLOSED LOOP PVP-I SCRUB]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed loop insulin delivery during labor and delivery
Trial: 29958022
Drug: Closed loop
RxNorm normalized name: Povidone Iodine 7.5% Topical application Liquid [OPERAND CLOSED LOOP PVP-I SCRUB]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed loop insulin delivery postpartum
Trial: 19592029
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg/kg (group P)
Trial: 19592029
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg/kg added to lidocaine (group A)
Trial: 19592029
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) solution (group S)
Trial: 10532133
Drug: Liquid diet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid diet, sennosides A and B, and a two-liter solution with PEG and electrolytes
Trial: 7768070
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (250 ml) before one oral and one intravenous dose of cyclosporine
Trial: 7768070
Drug: Intravenous cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclosporine (2.5 mg/kg infused for 3 hours)
Trial: 7768070
Drug: Oral cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine (7.5 mg/kg)
Trial: 1691392
Drug: Epinephrine (EPI)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine (EPI) infusion (20 ng kg‐1/min) during placebo
Trial: 1691392
Drug: Epinephrine (EPI)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine (EPI) infusion during beta 1‐selective beta‐adrenoceptor blockade with atenolol (50 mg once daily)
Trial: 1691392
Drug: Epinephrine (EPI)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine (EPI) infusion during nonselective beta‐blockade with bopindolol (1 mg once daily)
Trial: 1691392
Drug: Epinephrine (EPI)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine (EPI) infusion during stress tests
Trial: 15795147
Drug: Epinephrine 12.5
RxNorm normalized name: Epinephrine 12.5 microgram/mL and lidocaine hydrochloride 20 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 12.5 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Trial: 15795147
Drug: Epinephrine 25
RxNorm normalized name: EPINEPHRINE 250MCG 300D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 25 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Trial: 15795147
Drug: Epinephrine 50
RxNorm normalized name: epinephrine 500 MCG per 0.5 ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 50 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Trial: 15795147
Drug: Epinephrine 100
RxNorm normalized name: Epinephrine 100 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 100 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Trial: 15795147
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: bupivacaine 2.5 mg and fentanyl 25 microg only
Trial: 14576732
Drug: High-dose anthracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose anthracycline regimens, four cycles given every 15 days as induction lasting for ≤6 months.
Trial: 14576732
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy consolidation followed by autologous stem-cell transplantation (23 patients).
Trial: 14576732
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy regimens (69 patients).
Trial: 10868452
Drug: Caloric liquid
RxNorm normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caloric liquid bolus (280 kJ) containing paracetamol and 14C-D-xylose administered during late phase II of the intestinal MMC
Trial: 10868452
Drug: Caloric liquid
RxNorm normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caloric liquid bolus (280 kJ) containing paracetamol and 14C-D-xylose administered during phase I of the intestinal MMC
Trial: 6657887
Drug: Psychosomatic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosomatic group therapy (including autogenic training and functional relaxation)
Trial: 29476687
Drug: Aflibercept on
RxNorm normalized name: Aflibercept only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept on a monthly schedule
Trial: 29476687
Drug: Bevacizumab on
RxNorm normalized name: Bevacizumab only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab on a monthly schedule
Trial: 20854235
Drug: Perindopril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril plus indapamide (4 mg-1.25 mg/day)
Trial: 18439712
Drug: Apples (0.63
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apples (0.63 kcal/g energy density)
Trial: 18439712
Drug: Pears (0.64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pears (0.64 kcal/g energy density)
Trial: 18439712
Drug: Oat cookies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat cookies (3.7 kcal/g energy density)
Trial: 15621465
Drug: New protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New protocol (group 2) with oxytetracycline instilled in a fractionated-dose manner following frequent aspirations at 6h intervals
Trial: 11739065
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT) with sertraline
Trial: 11739065
Drug: Sertraline without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline without ERT
Trial: 8234999
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg p.o. administered for 60 minutes
Trial: 3318609
Drug: Intravenous cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefazolin (1 g) 30 minutes before gastrostomy
Trial: 3318609
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline as a placebo
Trial: 3318609
Drug: Intravenous cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefazolin (1 g)
Trial: 29231481
Drug: Auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular point sticking treatment (adhesive fabric with vaccaria seeds pressed at specific auricular points for 3 to 5 min, administered twice daily for one week)
Trial: 21483895
Drug: Three-implant-supported fixed
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-implant-supported fixed dentures (ISFDs)
Trial: 21483895
Drug: Two-implant-supported overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-implant-supported overdentures (IODs)
Trial: 10912666
Drug: Interferon plus
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon plus Ursodeoxycholic acid (UDCA) (13‐15 mg/kg/day)
Trial: 9454431
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide in crystalline suspension (Volon A 80, 2.0 ml) intrathecally via lumbar puncture on the 5th postoperative day (group A)
Trial: 8363378
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin (400 mg every 12 h)
Trial: 8363378
Drug: Intravenous ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ofloxacin (400 mg every 12 h, 1-h infusion)
Trial: 22159928
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of methylcobalamin (500 mcg, 1 ml solution, three times a week for two weeks)
Trial: 17388705
Drug: Olanzapine (15-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (15-20 mg/day)
Trial: 17388705
Drug: Haloperidol (15-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (15-20 mg/day) with additional blinded benztropine
Trial: 2081685
Drug: Levamisole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (150 or 200 mg once a week for 4 years)
Trial: 763217
Drug: Actovegin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actovegin (0.5 ml/kg/day for 14 days)
Trial: 763217
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution (equivalent amounts)
Trial: 26243249
Drug: Etanercept (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (10 mg) with bupivacaine (2 mL)
Trial: 26243249
Drug: Control (bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (bupivacaine [2 mL])
Trial: 22146946
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone and 5 mg tropisetron (group D+T)
Trial: 22146946
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone (group D)
Trial: 22146946
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tropisetron (group T)
Trial: 9834207
Drug: G-CSF treatment
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF treatment (300 microg/m2 intravenously over 1 hour from day 1 of PBSCT)
Trial: 1106445
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base (500 mg single dose)
Trial: 1106445
Drug: Erythromycin stearates
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearates (500 mg single dose)
Trial: 1106445
Drug: Erythromycin estolates
RxNorm normalized name: Erythromycin Estolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin estolates (500 mg single dose)
Trial: 1106445
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base (250 mg every 6 hours for 4 days)
Trial: 1106445
Drug: Erythromycin stearates
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearates (250 mg every 6 hours for 4 days)
Trial: 12075201
Drug: Biodegradable copolymer
RxNorm normalized name: Methacrylic Acid Copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodegradable copolymer screws (poly‐L‐lactic acid 82% and polyglycolic acid 18%)
Trial: 8757422
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (ddI) at 375 mg and 250 mg b.i.d. for body weight > 60 and < or = 60 kg, respectively
Trial: 8757422
Drug: Zidovudine (AZT)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (AZT) maintaining the current dosage
Trial: 6884233
Drug: Oral hyposensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hyposensitization (1,750,000 PNU, 3,500,000 NU)
Trial: 6884233
Drug: Parenteral hyposensitization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral hyposensitization (1,550 PNU, 3,100 NU)
Trial: 25606785
Drug: C1-inhibitor (C1-INH,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1-inhibitor (C1-INH, 20 IU/kg/dose)
Trial: 25606785
Drug: C1-inhibitor (C1-INH)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (C1-INH)
Trial: 23744509
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of HAV/MMRV/PCV-7 (Group 1)
Trial: 23744509
Drug: Non-concomitant administration
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-concomitant administration of HAV (Group 2)
Trial: 15154663
Drug: PS76A2 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS76A2 (10, 30, or 70 ng mistletoe lectin per ml)
Trial: 2525460
Drug: Turret nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turret nebulizer with albuterol (250, 250, 500, 1000 micrograms)
Trial: 2525460
Drug: Inspiron nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiron nebulizer with albuterol (250, 250, 500, 1000 micrograms)
Trial: 25176615
Drug: Entecavir 0.5mg
RxNorm normalized name: ENTECAVIR 0.5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.5mg daily combined with tenofovir 300 mg
Trial: 23350833
Drug: Fesoterodine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine (4 mg, with potential increase to 8 mg at week 4 or 8)